Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Medicare seeks to only cover patients who are enrolled in clinical trials evaluating Aduhelm, a drug that costs $28,000 a year.
Full Article
Biogen sinks 10% after Medicare limits coverage of new Alzheimer's drug Aduhelm
Business Insider
0 shares
1 views
You might like
Related news coverage
Biogen vs Eli Lilly: Jim Cramer weighs in
Invezz
Shares of Biogen Inc (NASDAQ: BIIB) are down about 8.0% on Wednesday after the U.S. Medicare programme refused to cover for its..
-
Biogen tumbles after Medicare lays out Aduhelm coverage plan
SeattlePI.com
-
Dish Network, Ally Financial rise; Biogen, Carvana fall
SeattlePI.com
-
Medicare limits coverage of $28,000-a-year Alzheimer's drug
SeattlePI.com
-
Medicare limits coverage Aduhelm, the $28,000-a-year Alzheimer's drug from Biogen
USATODAY.com